Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

1315687

	registered interest
	date	18/05/2021
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Prostate Cancer
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what estimate he has made of the number of men with suspected prostate cancer who were able to access and receive diagnostic tests through private sector capacity block purchased by the NHS during the covid-19 outbreak, by region.
	tabling member constituency	Carshalton and Wallington
	tabling member printed	Elliot Colburn
	uin	3175
	answer	answer is ministerial correction date of answer 24/05/2021 answer text <p>No estimate has been made.</p> answering member constituency Bury St Edmunds answering member printed Jo Churchill question first answered 24/05/2021 10:39:14 answering member 4380 label Biography information for Jo Churchill
	tabling member	4775 label Biography information for Elliot Colburn

1315688

	registered interest
	date	18/05/2021
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Prostate Cancer
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what plans he has to prioritise prostrate cancer in a new cancer strategy for England; and if he will make a statement.
	tabling member constituency	Carshalton and Wallington
	tabling member printed	Elliot Colburn
	uin	3176
	answer	answer is ministerial correction date of answer 24/05/2021 answer text <p>The Department’s cancer strategy is incorporated as part of the NHS Long Term Plan. Prostate cancer priorities are included as part of the Long Term Plan such as the introduction of a faster diagnosis standard. This includes the delivery of optimal timed diagnostic pathways for specific cancers, including prostate cancer.</p><p>Personalised stratified follow up pathways for prostate cancer are being launched across England to empower patients to take control of their care. Prostate cancer is one of the first three cancers for which this is being implemented.</p> answering member constituency Bury St Edmunds answering member printed Jo Churchill question first answered 24/05/2021 13:15:42 answering member 4380 label Biography information for Jo Churchill
	tabling member	4775 label Biography information for Elliot Colburn

1315689

	registered interest
	date	18/05/2021
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Prostate Cancer
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what steps he is taking to ensure that men with advanced prostate cancer have access to quality patient care and innovative treatments.
	tabling member constituency	Carshalton and Wallington
	tabling member printed	Elliot Colburn
	uin	3177
	answer	answer is ministerial correction date of answer 24/05/2021 answer text <p>Treatment options for prostate cancer are always expanding and in February 2021, NHS England and NHS Improvement’s specialised commissioning team announced that it would make available external beam radiotherapy to treat hormone sensitive, low volume prostate cancer. In addition to external beam radiotherapy, the National Institute of Health and Care Excellence will review several new treatment options for prostate cancer in the next 12 months.</p><p>Following treatment for prostate cancer, patients move to a Personalised Stratified Follow-Up pathway that suits their needs and ensures they can get rapid access to clinical support where they are worried that their cancer may have recurred. This stratified follow-up approach was established in all trusts for prostate cancer in 2020. In response to the pandemic, the NHS also made available a range of ‘COVID-19 friendly’ treatments, offering benefits such as fewer hospital visits or a reduced impact on the patient’s immune system. This includes targeted hormone therapies such as enzalutamide for prostate cancer treatment.</p> answering member constituency Bury St Edmunds answering member printed Jo Churchill question first answered 24/05/2021 12:56:39 answering member 4380 label Biography information for Jo Churchill
	tabling member	4775 label Biography information for Elliot Colburn

1302581

	registered interest
	date	15/03/2021
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Breast Cancer: Screening
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, if he will direct NHS England to prioritise women with dense breast tissue when tackling the cancer screening backlog accrued as a result of the covid-19 outbreak.
	tabling member constituency	Carshalton and Wallington
	tabling member printed	Elliot Colburn
	uin	169051
	answer	answer is ministerial correction date of answer 23/03/2021 answer text <p>In addressing the cancer screening backlog resulting from COVID-19, NHS England and NHS Improvement have made prioritisation decisions based upon expert clinical advice and engagement with Public Health England (PHE). On the basis of a United Kingdom National Screening Committee evidence review, PHE has advised that breast density measurements are not yet accurate enough to be safely used in routine breast screening. There is also no readily available breast density measurement for women currently in the programme. It is therefore not advisable or feasible to prioritise invitations for breast screening by breast tissue density.</p> answering member constituency Bury St Edmunds answering member printed Jo Churchill question first answered 23/03/2021 11:55:21 answering member 4380 label Biography information for Jo Churchill
	tabling member	4775 label Biography information for Elliot Colburn

1302582

	registered interest
	date	15/03/2021
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Breast Cancer: Screening
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the potential benefits of using breast density measurement software to identify women with dense breast tissue for the purpose of prioritising those women for breast cancer screening.
	tabling member constituency	Carshalton and Wallington
	tabling member printed	Elliot Colburn
	uin	169052
	answer	answer is ministerial correction date of answer 23/03/2021 answer text <p>In 2019, the United Kingdom National Screening Committee (UK NSC) commissioned a systematic review to look at the issue of breast density. The review found that breast density is related to risk of breast cancer. However, breast density measurements are not yet robust or repeatable enough, there is no ‘gold standard’ test to validate breast density measurements. For these reasons that the UK NSC recommended that additional screening with ultrasound after a negative mammography screening in women with dense breasts should not be introduced. More robust evidence is needed before risk stratification can be considered within the breast screening programme.</p> answering member constituency Bury St Edmunds answering member printed Jo Churchill question first answered 23/03/2021 12:41:42 answering member 4380 label Biography information for Jo Churchill
	tabling member	4775 label Biography information for Elliot Colburn

1302583

	registered interest
	date	15/03/2021
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Breast Cancer: Screening
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the potential merits of introducing tomosynthesis to digital mammography to improve the accuracy of breast screening.
	tabling member constituency	Carshalton and Wallington
	tabling member printed	Elliot Colburn
	uin	169053
	answer	answer is ministerial correction date of answer 23/03/2021 answer text <p>Research is underway in the Prospective Trial of Digital Breast Tomosynthesis, carried out by Kings College Hospital NHS Trust in breast screening. This trial involves 100,000 women participating in screening to assess whether tomosynthesis is a useful addition to the routine breast screening programme. The United Kingdom National Screening Committee will review the results of the research expected to be published in 2024.</p><p>Tomosynthesis has been approved for use in the National Health Service breast screening programme as an optional extra tool in the assessment of screen detected soft tissue breast abnormalities, following the primary screen.</p><p> </p> answering member constituency Bury St Edmunds answering member printed Jo Churchill question first answered 23/03/2021 12:32:09 answering member 4380 label Biography information for Jo Churchill
	tabling member	4775 label Biography information for Elliot Colburn

1302584

	registered interest
	date	15/03/2021
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Breast Cancer: Screening
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the potential merits of introducing AI-driven mammography to (a) support radiologists and (b) increase capacity in the breast cancer screening programme.
	tabling member constituency	Carshalton and Wallington
	tabling member printed	Elliot Colburn
	uin	169054
	answer	answer is ministerial correction date of answer 23/03/2021 answer text <p>There is currently no published evidence in large scale prospective trials that Artificial intelligence (AI) would be equivalent or better than the current model of having two independent human mammogram readers. AI continues to generate huge amounts of interest for its potential role in the NHS. There is interest in AI for breast screening, where it could replace a human reader of mammograms.</p><p>The United Kingdom National Screening Committee (UK NSC) and Public Health England have developed interim guidance for AI developers to help consider key metrics required that would assist the UK NSC to make a recommendation on the use of AI. Both are working with the NHS Accelerated Access Collaborative who are funding a large study in 2021 to understand whether AI can be a useful support to the programme. More information is available at the following link: <a href="https://www.england.nhs.uk/aac/" target="_blank">https://www.england.nhs.uk/aac/</a></p><p>More information about AI and screening can be found at the following link; <a href="https://phescreening.blog.gov.uk/2021/02/02/advice-for-nhs-breast-screening-services-on-the-use-of-ai/" target="_blank">https://phescreening.blog.gov.uk/2021/02/02/advice-for-nhs-breast-screening-services-on-the-use-of-ai/</a></p> answering member constituency Bury St Edmunds answering member printed Jo Churchill question first answered 23/03/2021 13:12:08 answering member 4380 label Biography information for Jo Churchill
	tabling member	4775 label Biography information for Elliot Colburn

1284072

	registered interest
	date	04/02/2021
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cancer: Health Services
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what methodology his (a) Department and (b) NHS England have used to calculate the volume of the backlog of cancer patients awaiting (a) screening and (b) treatment that has accrued as a result of the covid-19 outbreak; and if he will publish those calculations.
	tabling member constituency	Carshalton and Wallington
	tabling member printed	Elliot Colburn
	uin	149350
	answer	answer is ministerial correction date of answer 02/03/2021 answer text <p><strong> </strong></p><p>National Health Service screening programmes do not hold waiting lists, therefore there is no published waiting time data. Eligible patients are invited to participate in NHS screening programmes at intervals according to the specific programme.</p><p>Data sources used by for cancer treatment include cancer waiting times data which give month by month figures on activity, referrals and waiting times, as well as management information which can provide a week to week view of activity and the current scale of the waiting list. Hospital Episode Statistics, and the secondary uses service are used alongside specific sources of information such as the Radiotherapy Dataset or the Diagnostic Imaging Dataset. Data are considered by geography, provider trust, tumour pathway and treatment modality to pinpoint areas for further action.</p><p>From March, local systems will be expected to carry out local plans formed as part of the Cancer Services Recovery Plan and continue the progress that has already been made.</p> answering member constituency Bury St Edmunds answering member printed Jo Churchill question first answered 02/03/2021 16:49:33 answering member 4380 label Biography information for Jo Churchill
	tabling member	4775 label Biography information for Elliot Colburn

1280596

	registered interest
	date	26/01/2021
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cancer: Health Services
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what plans he has to (a) make an assessment of the effectiveness of the NHS Cancer Recovery Plan and (b) provide additional funding to improve capacity in cancer services to tackle the covid-19-outbreak-induced cancer treatment and diagnostic backlogs.
	tabling member constituency	Carshalton and Wallington
	tabling member printed	Elliot Colburn
	uin	143916
	answer	answer is ministerial correction date of answer 01/02/2021 answer text <p>The Cancer Recovery Plan aims to restore urgent referrals at least to pre-pandemic levels, to reduce the number of people waiting over 62 days from urgent referral and ensure sufficient capacity to meet demand. The latest published data for November 2020 showed urgent referrals 2% above pre-pandemic levels, the number of people waiting over 62 days 24% above pre-pandemic levels and the number of people starting a first cancer treatment within 31 days at 95% of pre-pandemic levels.</p><p>In August 2020, the National Health Service announced a £160 million initiative to extend access to ‘COVID-friendly’ cancer treatments, in October, issued £150 million in funding to expand diagnostic capacity. A further £325 million funding of diagnostics equipment was announced in November’s Spending Review and cancer patients will continue to be prioritised within the NHS and will benefit from the additional £1 billion to begin tackling the elective backlog. Departmental officials regularly engage with their counterparts at HM Treasury regarding upcoming fiscal events.</p><p><strong> </strong></p> answering member constituency Bury St Edmunds answering member printed Jo Churchill grouped question UIN 143917 question first answered 01/02/2021 14:31:13 answering member 4380 label Biography information for Jo Churchill
	tabling member	4775 label Biography information for Elliot Colburn

1280597

	registered interest
	date	26/01/2021
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cancer: Health Services
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what recent discussions officials of his Department have had with officials of the Treasury on ensuring that the 2021 Spring Budget includes sufficient funding for cancer (a) diagnostic and (b) treatment services to help tackle the increasing backlogs in those areas that have accrued as a result of the covid-19 outbreak.
	tabling member constituency	Carshalton and Wallington
	tabling member printed	Elliot Colburn
	uin	143917
	answer	answer is ministerial correction date of answer 01/02/2021 answer text <p>The Cancer Recovery Plan aims to restore urgent referrals at least to pre-pandemic levels, to reduce the number of people waiting over 62 days from urgent referral and ensure sufficient capacity to meet demand. The latest published data for November 2020 showed urgent referrals 2% above pre-pandemic levels, the number of people waiting over 62 days 24% above pre-pandemic levels and the number of people starting a first cancer treatment within 31 days at 95% of pre-pandemic levels.</p><p>In August 2020, the National Health Service announced a £160 million initiative to extend access to ‘COVID-friendly’ cancer treatments, in October, issued £150 million in funding to expand diagnostic capacity. A further £325 million funding of diagnostics equipment was announced in November’s Spending Review and cancer patients will continue to be prioritised within the NHS and will benefit from the additional £1 billion to begin tackling the elective backlog. Departmental officials regularly engage with their counterparts at HM Treasury regarding upcoming fiscal events.</p><p><strong> </strong></p> answering member constituency Bury St Edmunds answering member printed Jo Churchill grouped question UIN 143916 question first answered 01/02/2021 14:31:13 answering member 4380 label Biography information for Jo Churchill
	tabling member	4775 label Biography information for Elliot Colburn